182 related articles for article (PubMed ID: 11861816)
21. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.
Smit JW; Schinkel AH; Weert B; Meijer DK
Br J Pharmacol; 1998 May; 124(2):416-24. PubMed ID: 9641561
[TBL] [Abstract][Full Text] [Related]
22. Lung tissue distribution after intravenous administration of grepafloxacin: comparative study with levofloxacin.
Yamamoto H; Koizumi T; Hirota M; Kaneki T; Ogasawara H; Yamazaki Y; Fujimoto K; Kubo K
Jpn J Pharmacol; 2002 Jan; 88(1):63-8. PubMed ID: 11855679
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of grepafloxacin.
Efthymiopoulos C
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():35-43. PubMed ID: 9484872
[TBL] [Abstract][Full Text] [Related]
24. The pharmacological role of P-glycoprotein in the intestinal epithelium.
Van Asperen J; Van Tellingen O; Beijnen JH
Pharmacol Res; 1998 Jun; 37(6):429-35. PubMed ID: 9695116
[TBL] [Abstract][Full Text] [Related]
25. Limited role of P-glycoprotein in the intestinal absorption of cyclosporin A.
Lee YJ; Chung SJ; Shim CK
Biol Pharm Bull; 2005 Apr; 28(4):760-3. PubMed ID: 15802827
[TBL] [Abstract][Full Text] [Related]
26. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
27. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Sparreboom A; van Asperen J; Mayer U; Schinkel AH; Smit JW; Meijer DK; Borst P; Nooijen WJ; Beijnen JH; van Tellingen O
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):2031-5. PubMed ID: 9050899
[TBL] [Abstract][Full Text] [Related]
28. Alteration of pharmacokinetics of grepafloxacin in type 2 diabetic rats.
Watanabe M; Kobayashi M; Ogura J; Takahashi N; Yamaguchi H; Iseki K
J Pharm Pharm Sci; 2014; 17(1):25-33. PubMed ID: 24735760
[TBL] [Abstract][Full Text] [Related]
29. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice.
Sasabe H; Kato Y; Suzuki T; Itose M; Miyamoto G; Sugiyama Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):648-55. PubMed ID: 15131241
[TBL] [Abstract][Full Text] [Related]
30. Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.
Hirota M; Totsu T; Adachi F; Kamikawa K; Watanabe J; Kanegasaki S; Nakata K
J Infect Chemother; 2001 Mar; 7(1):16-21. PubMed ID: 11406752
[TBL] [Abstract][Full Text] [Related]
31. Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats.
Zhao YL; Cen XB; Ito M; Yokoyama K; Takagi K; Kitaichi K; Nadai M; Ohta M; Takagi K; Hasegawa T
Antimicrob Agents Chemother; 2002 May; 46(5):1522-8. PubMed ID: 11959591
[TBL] [Abstract][Full Text] [Related]
32. [Influence of ion pump-inhibiting drugs on the accumulation of ofloxacin and grepafloxacin in human polymorphonuclear leukocytes].
Orero A; Cantón E; Pemán J; Velert MM; Bermejo MV
Rev Esp Quimioter; 2002 Dec; 15(4):352-9. PubMed ID: 12587041
[TBL] [Abstract][Full Text] [Related]
33. Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
Shakibaei M; Baumann-Wilschke I; Rücker M; Stahlmann R
Arch Toxicol; 2002 Jan; 75(11-12):725-33. PubMed ID: 11876506
[TBL] [Abstract][Full Text] [Related]
34. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion.
Veau C; Leroy C; Banide H; Auchère D; Tardivel S; Farinotti R; Lacour B
Nephrol Dial Transplant; 2001 Aug; 16(8):1607-14. PubMed ID: 11477162
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of cyclosporin A on p-glycoprotein function in peripheral nerves of mice treated with doxorubicin and vinblastine.
Saito T; Zhang ZJ; Ohtsubo T; Noda I; Tokuriki M; Shibamori Y; Yamamoto T; Saito H
Acta Otolaryngol; 2004 Apr; 124(3):313-7. PubMed ID: 15141761
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Hoetelmans RM; Beijnen JH; Schinkel AH
Mol Pharmacol; 2001 Apr; 59(4):806-13. PubMed ID: 11259625
[TBL] [Abstract][Full Text] [Related]
37. The clinical pharmacokinetics of levofloxacin.
Fish DN; Chow AT
Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
[TBL] [Abstract][Full Text] [Related]
38. Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats.
Passchier J; van Waarde A; Doze P; Elsinga PH; Vaalburg W
Eur J Pharmacol; 2000 Nov; 407(3):273-80. PubMed ID: 11068023
[TBL] [Abstract][Full Text] [Related]
39. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum.
Smith AJ; Mayer U; Schinkel AH; Borst P
J Natl Cancer Inst; 1998 Aug; 90(15):1161-6. PubMed ID: 9701366
[TBL] [Abstract][Full Text] [Related]
40. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies.
Rodríguez-Ibáñez M; Nalda-Molina R; Montalar-Montero M; Bermejo MV; Merino V; Garrigues TM
Eur J Pharm Biopharm; 2003 Mar; 55(2):241-6. PubMed ID: 12637104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
